1.
|
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ECTCL1, NCT00221039
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-1495, E1495
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: no age specified
Sponsor: NCI
Protocol IDs: NCI-79-C-70, NCI-NMOB-816, NCI-T83-1451N, NCI-N81-900, N81-0900
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: NU-83H3, NCI-V85-0142
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: over 18
Sponsor:
Protocol IDs: UCHSC-88036, NCI-V88-0558
|
|
6.
|
Phase: Phase II, Phase I
Type: Supportive care
Status: Closed
Age: 18 to 65
Sponsor: Other
Protocol IDs: 2006.409, NCT00930566
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: over 18
Sponsor: Other
Protocol IDs: YALE-HIC-7679, NCI-V94-0554
|
|
8.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Closed
Age: any age
Sponsor: Other
Protocol IDs: JHOC-9319, JHUSM-FDR001240, NCI-V96-0896
|
|
9.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Closed
Age: not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: RPCI-DS-96-12, THERAKOS-RPCI-DS-96-12, NCI-G97-1239
|
|
10.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MILL-61896, LIGAND-MILL-61896, NU-IRB-837-002, NCT00030589
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor: Other
Protocol IDs: MDA-DM-87100, NCI-V88-0342
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Temporarily closed
Age: 18 to 70
Sponsor: NCI
Protocol IDs: ECOG-E1902, NCT00045305, E1902
|
|
13.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000285659, ECOG-1402, E1402, NCT00057954
|
Mobile | Español
